Thymic Hyperplasia in Myasthenia Gravis: Immuno-Histological Abnormalities and Responsiveness to Recombinant IL2
Myasthenia Gravis (MG) is an autoimmune disorder of neuromuscular transmission characterized by the presence of autoantibodies directed against acetylcholine receptor (AChR), which are detected in more than 85 % of patients’ sera (1). The role of the thymus in MG has been strongly suggested by the favorable clinical effects of thymectomy and by the high incidence of thymic abnormalities (15–20 % thymomas and 50 % hyperplastic thymuses) (2).
KeywordsDouble Label Experiment Thymic Hyperplasia Thymic Lymphocyte Thymic Abnormality High Proliferative Response
Unable to display preview. Download preview PDF.
- 2.G.D. Levine. Pathology of the thymus in myasthenia gravis: current concepts. In.: Dau P.C., ed. Plasmapheresis and the immunobiology of myasthenia gravis. Boston: Houghton Mifflin: 113–123 (1979).Google Scholar
- 8.S. Berrih-Aknin, E. Morel, F. Raimond, S. Safar, C. Gaud, J.P. Binet, P. Levasseur and J.F. Bach. The role of the thymus in myasthenia gravis. Immunohistological and immunological studies in 115 cases. Ann. N.Y. Acad. Sci, (in press).Google Scholar
- 12.S.M. Hammer and J.M. Gillis. Effects of recombinant inter-leukin-2 on resting human T lymphocytes. J. Biol. Resp. Modifers. 5: 36–44 (1986).Google Scholar